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Improving the FDA Approval Process
Anup Malani, Oliver Bembom and Mark van der Laan1

Abstract. The FDA employs an average-patient standard when reviewing drugs: it
approves a drug only if is safe and effective for the average patient in a clinical trial. It is
common, however, for patients to respond differently to a drug. Therefore, the average-patient
standard can reject a drug that benefits certain patient subgroups (false negative) and even
approval a drug that harms other patient subgroups (false positives). These errors increase the
cost of drug development – and thus health care – by wasting research on unproductive or
unapproved drugs. The reason why the FDA sticks with an average patient standard is concern
about opportunism by drug companies. With enough data dredging, a drug company can always
find some subgroup of patients that appears to benefit from its drug, even if it truly does not.
In this paper we offer alternatives to the average patient standard that reduce the risk of
false negative without increasing false positives from drug company opportunism. These
proposals combine changes to institutional design – evaluation of trial data by an independent
auditor – with statistical tools to reinforce the new institutional design – specifically, to ensure
the auditor is truly independent of drug companies. We illustrate our proposals by applying them
to the results of a recent clinical trial of a cancer drug (motexafin gadolinium). Our analysis
suggests that the FDA may have made a mistake in rejecting that drug.

1

University of Chicago Law School, Resources for the Future and National Bureau of Economic Research;
Department of Statistics, University of California-Berkeley; and Department of Statistics, University of CaliforniaBerkeley, respectively. We thank Richard Miller for access to the data from the Phase III motexafin gadolinium
(MgD) trials. We thank Glenn Cohen, Adam Cox, Jack Calfee, Richard Epstein, Jake Gersen, Dan Ho, Jonathan
Masur, Richard Miller, Lars Noah, Ben Roin, participants at the AEI conference, “Oncology Drug Development:
Rethinking FDA Oversight,” March 13-14, 2008, and workshop participants at the University of Chicago Law
School for helpful comments. Malani thanks the Milton and Miriam Handler Foundation for financial support. In
the interest of full disclosure, two of the authors, Bembom and van der Laan work for Target Analytics, Inc., which
was hired by an investor in Pharmacyclics to prepare a statistical analysis of the data from the MgD trials. The data
analysis for this particular paper was conducted after Pharmacyclics’ application for FDA approval for MgD was
rejected by the agency in Dec. 2007. B. Jungbauer, Pharmacyclics' Xcytrin Gets FDA "Not Approvable" For
NSCLC Patients With Brain Metastases, The Pink Sheet (Dec. 28, 2007).

1

Introduction
Only one out of every five drugs that begin clinical trials emerges successfully from that
testing. This high failure rate explains a substantial portion of the exploding costs of health care
in America. Although it costs roughly $300 million to conduct a full battery of clinical trials on
a drug, these costs can only be billed to drugs that are successful enough to be approved by the
U.S. Food and Drug Administration (FDA). Dividing the cost of conducting trials by the number
of successful drugs inflates the cost of clinical testing to $800 million per approved drug.3 In this
manner, the trial failure rate magnifies the already growing cost of conducting clinical trials.4 As
a result, the cost of prescription drugs has grown twice as fast as the cost of the other two major
components of health care costs, hospital stays and physician care, helping push the overall cost
of healthcare to 16% of GDP.5
2

There are two reasons for why so many drugs might fail clinical trials. First, most drugs
might not work. Perhaps scientists have plucked the low-hanging pharmacological fruit and
drug companies now face diminishing returns on their research investments. Second, clinical
trials might fail to identify all the drugs that work. If the first explanation is correct, there is little
that can be done to reduce the cost of prescription drugs. However, the first explanation depends
on the second explanation being incorrect. If trials cannot identify all safe and effective drugs,
then one cannot know if we have run out of such drugs. This paper suggests that the high failure
rate of drugs is partly due to the failure of trials to identify good drugs and proposes a regulatory
solution to the problem.
The problem with clinical trials is not so much how they are designed, but rather how the
information they produce is evaluated. The FDA uses an “average patient standard” to
determine whether a drug is safe and effective. That is, the FDA compares how the average trial
participant on a drug compares to the average trial participant on placebo. If the former does
better than the latter, then the drug is approved. Otherwise not. If a drug works in some patients
2

More precisely, out of every five drugs for which an Investigational New Drug (IND) application is filed with the
U.S. Food and Drug Administration (FDA) to begin clinical testing, only one results in a New Drug Application
(NDA) for marketing approval from the FDA. Christopher P. Adams and Van V. Brantner, Estimating The Cost Of
New Drug Development: Is It Really $802 Million?, 25 Health Aff. 420, 422 (Exhibit 1) (2006).
3

Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski, The price of innovation: new estimates of drug
development costs, 22 J. Health Econ. 151, 166 (2003). The reason one cannot simply divide the $200 million
estimate by the probability of success during clinical testing (0.2 = 1/5) is that not all drugs complete a full battery of
clinical tests.
4

Id. at 167.

5

The cost of prescription drugs grew, on average, by 12% from 1996-2006. By contrast, hospital and physician
costs grew by roughly 6% per year during that period. Kaiser Family Foundation, Prescription Drug Trends 1
(2008), available at http://www.kff.org/rxdrugs/upload/3057_07.pdf (last visited Mar. 1, 2010).
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but not others, however, the average patient standard may reject drugs that are effective for some
patients. These drugs may be effective for a subset of trial participants, just not the average
participant. In short, the average patient standard suffers from false negatives.
It is common for drugs to have different effects in different patients, a phenomenon
statistician call “heterogeneity in treatment effects”. For example, Anthrotec (Pfizer) is an
effective treatment for osteoarthritis for patients who develop ulcers when certain common pain
medications.6 But a key ingredient in Anthrotec – misoprostol – is documented to induce labor
and used for medical elective abortion.7 Therefore, while Anthrotec is generally effective for
pain relief, it is contraindicated8 for pregnant women because of its abortifacient effects.
Another example is isoniazid, a widely used chemotherapy drug used to treat patients with
tuberculosis. Different patients metabolize the drug at different rates and a patient’s rate of
metabolization of the drug can be discovered through genetic testing. It has been demonstrated
that the drug is effective in patients who metabolize the drug at a slow rate but not among
patients who metabolize it at a fast rate.9
The FDA is aware of the risk of false negatives under the average patient standard. The
reason they stick with the standard is that they think the alternative is to allow drug companies to
mine data from clinical trials to find subgroups of participants who show benefit from the drug.
This alternative – which is called post hoc subgroup analysis10 – just replaces the risk of false
negatives with false positives. The more subgroups a drug company examines, the more likely
they are to find one that shows improvement on their drug, whether or not their drug actually
works. Statisticians call this the risk of spurious correlation from “multiple testing”. Drug
companies have a financial incentive to ignore – and even promote – this risk. They have

6

Anthrotec is diclofenac sodium plus misoprostol. Osteoarthritis is pain and inflammation caused by the breakdown
of cartilage in a patient’s joints. The pain medications that cause ulcers are non-steroidal anti-inflammatory drugs
(NSAIDs). The drug is made by Pfizer.
7

See Goldberg et al., Misoprostol and Pregnancy, 34(1) New Eng. J. Med. 38 (Jan. 4, 2001).

8

Arthrotec product insert at 1, available at FDA, Label and Approval History – Arthrotec, Labeling revision, Aug.
24, 2007, available at http://www.fda.gov/cder/foi/label/2007/020607s010lbl.pdf (last visited Mar. 7, 2008).
9

Gordon A. Ellard and Patricia T. Gammon, Pharmacokinetics of isoniazid metabolism in man, 4 J. Pharmokinetics
& Pharmacodynamics 83, 83-84 (1976).
10

To be precise, subgroup analysis is statistical evaluation of the effect of a drug on one or more subgroups of the
subjects in a clinical trial. Post hoc subgroup analysis, in particular, is the estimation of treatment effects in
subgroups that were not specified prior to the start of the trial. Instead the statistical analysis is performed on
subgroups identified from the data after the trial had begun or was completed.
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invested millions in lab research and development; they can only recoup this if their drug is
approved.11
It seems patients are stuck between a rock and a hard place: too many false negatives
with the FDA’s average patient standard or too many false positives with drug company data
mining. This paper offers a third option – actually, a series of proposals – that reduces false
negatives without increasing false positives. This will increase the rate of approval only for
effective drugs, and reduce the waste of research expenditures.
The problem we identify with clinical trial is not their design but the way the FDA and
drug companies interpret the data from trials. Our first proposal, however, is to change in the
design of trials to reduce errors from the average patient standard. To understand the change,
some additional background on FDA policy is required. While the FDA rules out post hoc
subgroup analysis due to the risk of false positives, it does allow companies to identify
subgroups of patients they plan to study before they conduct a trial. That is, companies are
permitted to select subgroups of patients from the overall population to enroll, but they may not
select subgroups of patients from those already enrolled in a trial to demonstrate that a drug
works. The reason is that the latter approach lets drug companies “peek” at the answers before
giving the test. But the FDA’s compromise does not really address the false negative risk with
the average patient standard. Drug companies may not know which subgroups of patients will
benefit from a drug before testing the drug on a broad population of patients.
Therefore, our first proposal is to identify treatment-sensitive subgroups using an
“adaptive group sequential design” trial. In standard trials, patients are typically assigned to the
treatment or control group according to a pre-set randomization scheme and remain in their
assigned groups. In an adaptive design, new patients can be randomized to treatment or control
based on the performance of patients previously enrolled in the trial. If a certain subgroup of
participants seem to be doing better than others based on early returns, the drug company could
selectively enroll more patients from that subgroup in the general population as the trial
progresses. The goal is to identify treatment-sensitive subgroups based on data from early
enrollees in order to power up analysis of those subgroups among later enrollees.
Our second proposal – actually a pair of proposals – focuses on fixing post hoc subgroup
analysis to reduce data mining by drug companies. These proposals combine institutional design
– evaluation of trial data by an independent auditor – with statistical tools to reinforce the
institutional design – specifically, to ensure the auditor is truly independent.

11

If the FDA knew the number of subgroups the sponsor sampled in search of a positive response the FDA could
limit the risk of spurious correlation by employing statistical corrections for multiple testing, such as raising the pvalue required to demonstrate statistical significance. Unfortunately, the FDA will rarely be able to verify this
number. (We will discuss corrections for multiple testing at greater length in the text accompanying note 43.)
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Specifically, our proposal would permit post hoc subgroup analysis so long as it were
performed by an independent auditor rather than the drug company. We have learned from the
Enron and MCI Worldcom scandals, however, that independent auditors are not truly
independent.12 They may be indirectly compromised by career concerns. They may seek to
provide optimistic assessments of firms in the hope that they will subsequently be employed by
those firms for other auditor work. The same would be true of an outside statistician auditing
data from a company’s clinical trial. To address this concern, our second proposal suggests
statistical algorithms that prevent the independent auditor from identifying subgroups in a
manner that would financially benefit drug companies but would not help patients. These
algorithms may be thought of as veil of ignorance rules13 because they blind the auditor to
information that is required for the auditor to help the drug company.
Our most promising algorithm is what we call “split-sample analysis.” This algorithm
would give the auditor access only to a random subsample of the trial data as selected by the
FDA. The consultant would be asked to identify subgroups with post hoc subgroup analysis on
this “exploratory” sample. The drug company would then be permitted to seek drug approval for
a subgroup identified by the auditor under two conditions. First, it can only obtain approval for a
subgroup if the drug was significantly effective and safe for that subgroup in the remainder of the
trial sample, which we call the “confirmatory” sample. Second, statistical significance14 will be
judged according to a higher standard to account for the risk of spurious correlation due to
multiple testing bias. The larger the number of subgroups identified by the auditor, the stricter
the standard of statistical significance the company would have to meet.15
This algorithm protects against false positives in two ways. Because the auditor does not
have access to confirmatory sample, it cannot help the drug company out by choosing subgroups
that respond positively only in the confirmatory sample. Nor can the consultant help the drug
company simply by identifying a large number of subgroups based on the exploratory sample
because the sponsor pays a multiple-testing penalty in the confirmatory subsample for each
additional subgroup that the auditor identifies.

12

See Joel S. Demski, Corporate Conflicts of Interest, 17 J. Econ. Persp. 51, 57 (2003).

13

For a discussion of this class of rules, see Adrian Vermeule, Veil of Ignorance Rules in Constitutional Law, 111
Yale L. J. 399 (2001).
14

Statistical significance is conventionally defined as having a p-value less than or equal to 0.05. The p-value of a
statistical estimate is one minus the probability that the estimate is different from zero, which signifies no treatment
effect. In other words, if p < 0.05, then it can be said that we are more than 95% sure that the estimated treatment
effect is different than zero.
15

Our proposal would let the drug company choose the number of subgroups the auditor should identify to ensure
the auditor did not “tank” the drug company by simply identifying too many subgroups.
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To illustrate the potential benefit of increased flexibility in the drug approval process and
to demonstrate how our statistical algorithms could address the data manipulation problem, we
conduct a case study of motexafin gadolinium (MGd), a drug for lung cancer patients whose
tumors have spread to their brain and are threatening to induce dementia. In a key clinical trial,
the drug’s maker Pharmacyclics was unable to show that the average participant experienced a
statistically significant benefit from the drug.16 This failure may have been driven, however, by
poor results among patients who had already taken chemotherapy for their cancer. Among the
patients who were newly diagnosed and had not yet received any chemotherapy,17 the drug
appeared to significantly delay the onset of dementia. Despite this possibility, the FDA rejected
the drug.18 Mimicking the role of outside auditors, we apply our proposed statistical algorithms
to correct for bias due to any opportunistic behavior by the drug company. We find that one of
our algorithms would surely have validated the company’s claims and the other – split-sample
analysis – would have validated them with probability 0.11. That is, there is at least a one-in-ten
chance that a truly independent audit would have led to the approval of MGd.
Before we turn to the meat of the paper, we should clarify three things about our
proposals. First, while we advocate a change in how the FDA evaluates data from clinical trials,
we do not advocate lowering the FDA’s standard for approving drugs. Our proposals would all
continue to require that a drug be shown safe and effective with 95% confidence in order to be
approved.
Second, our proposals can be used to eliminate false positives as well as false negatives.
Although a drug may not have side effects for the average patient, it may have prohibitive side
effects for a subgroup of patients. Yet such a drug might be approved under the FDA’s average
patient standard. Our proposals for identifying subgroups of patients who benefit from a drug
can equally be used to identify subgroups of patients who would be harmed by a drug. While
there may be little reason to worry that a drug company will exaggerate the harm from a drug,
some have expressed concern that the FDA is overly risk averse or antagonistic to drug
companies and might exaggerate the harm from a drug.19 Our proposals can be used to ensure
that an outside auditor is truly independent of FDA influence and thus does not spuriously
identify subgroups harmed by a drug.
Finally, our proposals – especially the split-sample algorithm – highlight the potential
that statistical veil of ignorance rules can promote auditor independence. This is true for whether
16

See infra text accompanying notes 71 and 73.

17

Their tumors tended to be more resilient as they had already survived previous treatment.

18

See Jungbauer, supra note 1.

19

See, e.g., Henry I. Miller and David R. Henderson, The FDA’s Risky Risk-Aversion, Policy Review 5 (Oct. & Nov.
2007).
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the target of an audit is a clinical trial, a tax filing, or a report to shareholders. In short, our
algorithms may have utility in other areas of where law enforcement is concerned about
dishonest reporting by private companies.
The remainder of the paper has the following structure. Section 1 explains how the FDA
currently handles heterogeneous treatment response. Section 2 discusses the problem of spurious
correlation and opportunism associated with post hoc subgroup analysis. Section 3 presents our
proposals for controlling opportunism by drug companies. Section 4 examines data from the
MGd trial to illustrate the new statistical algorithms we propose. Finally, the conclusion
discusses, inter alia, how our proposals might be used to root out harmful drugs.
1.

FDA policy on heterogeneity in treatment response

The Food, Drug and Cosmetics Act requires that a company seeking marketing approval
for a new drug – also called the drug sponsor – demonstrate to the FDA that the drug is safe and
effective.20 This demonstration typically requires three phases of clinical testing. In Phase I, the
sponsor conducts a small clinical study, usually on health individuals, to demonstrate that a
clinically useful dose is not toxic for patients. In Phase II, the sponsor conducts a medium-sized
study on sick patients to provide evidence that the drug has some clinical benefit in humans and
warrants further clinical testing. In Phase III, the sponsor conducts two large-scale, controlled
clinical trials, again in sick patients, to demonstrate that the drug is both effective and has
relatively tolerable side effects.21
Although regulations do not spell out exactly the evidentiary standard to which the FDA
holds a new drug, the FDA has issued a guidance that emphasizes a drug should evaluated based
on all the patients that enroll in a trial22 and that requires the rate of false positive findings be set
to 5 percent.23 The implication – borne out by practice – is that the FDA judges the efficacy of a
drug by the difference between average outcomes in the treatment and control arms of a trial.
20

21 U.S.C. § 355(d).

21

Peter Barton Hutt and Richard A. Merrill, Food and Drug Law: Cases and Materials 527 n. 2 (2d ed. 1991). For
a more detailed analysis of the two-trial requirement, see Jennifer Kulynych, Will FDA Relinquish the “Gold
Standard” for New Drug Approval? Redefining “Substantial Evidence in the FDA Modernization Act of 1997, 54
Food & Drug L. J. 127, 129-130 (1999) (explaining that a second trial is due to the scientific requirement of
replication, that the requirement is occasionally waived, and that biologics are less likely to face this requirement).
22

This is called the intent-to-treat population. It includes even the subjects that drop out. See Food and Drug
Agency, International Conference on Harmonisation; Guidance on Statistical Principles for Clinical Trials,
Availability, 63(179) Fed. Reg. 49583, 49593 (Sept. 16, 1998) (henceforth “Statistical Guidance” (§5.2.1 Full
Analysis Set). The alternative is to evaluate the drug on the per-protocol population. In this case the drug is
evaluated only among subjects who enroll, do not drop out, and follow all trial procedures.
23

Id. at 49291 (§3.5 Sample Size).
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The FDA understands that there is heterogeneity of treatment effects across patient
subgroups.24 But it only accommodates this heterogeneity in a limited way. To begin with, it
encourages sponsors to specify prior to conducting a trial – or in statistic parlance, specify a
priori – the subgroups they plan to analyze.25 When this is done, sponsors must account for the
risk of spurious correlation due to multiple testing bias when setting their initial sample size and
when analyzing data from a trial.26 The FDA guidance does not explicitly state that significant
treatment effects among a priori specified subgroups can be the basis for drug approval, but it
does not rule it out.
In many cases, however, the sponsor may not have enough information prior to trials to
identify subgroups that may be especially sensitive to treatment. Even if it did, the FDA would
require the sponsor to increase sample size so that its study gathers sufficient statistical
information – or “power” – to accurately estimate treatment effects in those subgroups.27 This
additional cost may outstrip the financial resources available to many sponsors.
The FDA acknowledges that it will not always be possible to identify subgroups a priori
and that exploratory analysis of trial data may be required to identify subgroups.28 The FDA’s
24

Id. at 49589 (§3.2 Multicenter Trials).

25

Id. at 49595 (§5.7 Subgroups, Interactions, and Covariates).

26

Id. at 49587 (§2.2.5 Multiple Primary Variables). The agency recognizes that the corrections are less severe
where subgroups overlap and therefore produce correlated test statistics. If two subgroups are mutually exclusive,
the outcomes across groups are statistically independent. The appropriate adjustment for multiple testing bias is the
Bonferroni adjustment, which is described in Section 2. If the two subgroups overlap in part, the outcomes of the
groups will be positively correlated. In that case the failure of a test on one group will contribute to the failure of a
test for the overlapping second group. This reduces the risk of spurious results from statistical tests on the second
group. Therefore, something weaker than the Bonferroni adjustment is required to correct for multiple testing bias.
27

The basic formula for how large the sample in each subgroup must be to ascertain a treatment effect is

(
)
. In this formula, is how sensitive the researcher wants the estimate to be. In other words,
the formula gives the sample size required to identify treatment effects that are at least as large as . The formula
also depends on , the variance of the treatment effect from the drug. The larger the variance, the more the noise in
the data and thus the larger the sample size required to identify a treatment effect as small as . Usually the
researcher estimates from previous studies of the drug or the disease. The crucial statistical parameters are
,
which determines defines the confidence level of the analysis, and , which determines the power of the analysis.
The higher is the confidence level of the analysis, the lower is the chance of a false positive. A confidence level of
95% (i.e.,
) means that the probability that a significant result is false is just 5%. The critical value for this
level of confidence in a two-sided test with a normal distribution is
. The higher is the power of an
analysis, the lower is the chance of a false negative. A power level of 80% (
) means that the probability that
a drug with a positive treatment effect is mistakenly reported as having an insignificant treatment effect is 20%. The
critical value for this level of power is
As is apparent from the formula, greater higher confidence
levels and power require larger sample size.
28

Id. at 49595 (§5.7).
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approach to subsequent so-called post hoc subgroup analysis29 depends on the average treatment
effect in the full trial population and whether the outcome at issue concerns efficacy or safety.
If the sponsor cannot demonstrate that the average treatment effect is sufficient that the
drug will be approved for the full trial population, post hoc subgroup analysis by itself cannot be
used to obtain approval for a subgroup.30 The FDA has not approved a single drug solely on the
basis of post hoc subgroup analysis.31 The FDA does permit a sponsor to use post hoc subgroup
analysis identify a subgroup and then to conduct a subsequent trial on that subgroup to confirm
the findings of the subgroup analysis. But another trial can be very costly.32 And there is no
indication that the FDA allows sponsors to combine or “pool” the data from the subgroup in the
initial trial with data on the subgroup from the subsequent confirmatory trial to establish a
significant positive result for the subgroup across the two trials.33 Such a combination would
mitigate the sample size requirement – and hence costs – for the confirmatory trial.
Even if the sponsor is able to demonstrate that its drug is on average safe and effective
for the full trial population in the initial trial, the FDA may require the sponsor to demonstrate
the drug is effective and safe for subgroups defined by the agency in order to validate the results
for the full trial population. FDA guidelines identify subgroups defined by centers in multicenter
trials as one such check on the consistency of the trial’s main results,34 but clinically and
biologically defined subgroups have also been suggested.35 If certain subgroups do not show
efficacy or show side effects, the FDA may require that the drug label state it is indicated only
for the subpopulations where it has been demonstrated both effective and safe. For example,
following the Val-HeFT trial of 160 mg valsartan for patients with heart failure, the FDA only
approved the drug for patients who are intolerant to ACE inhibitors. The reason was that in the
full trial population the drug was superior to placebo only with respect to only one (combined
mortality and morbidity) of the two outcomes studied.36 (The other outcome was mortality
29

See note 10 for a precise definition of post hoc subgroup analysis.

30

Id. at 49595 (§5.7). See also John Powers et al., FDA Evaluation of Antimicrobials: Subgroup Analysis, Letter to
Editor, 126(6) Chest 2298 (June 2005).
31

Aldo P. Maggioni, et al., FDA and CPMP Rulings on Subgroup Analyses, 107 Cardiology 97, 99 (2007).

32

It is difficult to estimate from published data the cost of individual trials but it is possible to estimate the cost of
different phases of clinical testing. The out-of-pocket plus opportunity costs of phase I are $45.7 million, phase II
are $65.1 million, and phase III are $205.5 million. See DiMasi, et al., supra note 3, at 162 (table 1) and 165 (table
3). If phase III involves just two trials, then the cost of per phase III trial is over $100 million.
33

We examine this approach in infra note 49.

34

FDA, Statistical Guidance, supra note 22, at 49589 (§3.2)

35

See Powers et al., supra note 30, at 2298.

36

The primary endpoint of a trial is the outcome on which the treatment is judged.
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alone.) However, the drug was superior on both outcomes in the non-ACE subgroup.37 The
FDA may also require the sponsor for a drug with an uneven or uncertain safety profile to
conduct Phase IV post-approval trials. If the Phase IV trials reveal dangerous side effects, FDA
has the ability to alter a drug’s labeling to reflect those risks or to yank a drug from the market.
In short, the FDA takes a conservative and asymmetric approach with respect to subgroup
analysis.38 If subgroups are identified prior to trial, they may positively influence approval so
long as the sponsor powers the study to address multiple testing concerns. If subgroups cannot
be identified prior to trial, post hoc subgroup analysis can only be used to negatively influence
approval or to justify new, costly trials.39
It is worth noting that the FDA’s approach – judging drugs largely on the basis of average
treatment effects – implicitly assumes that doctors are very bad at matching the right patient
subgroups to drugs.40 To understand why, observe that the average treatment effect of a drug
(relative to control ) is equal to its positive treatment effect among patient subgroups that
benefit from the drug (i.e.,
) plus its negative treatment effects among those who do not
(i.e.,
):
(

)

(

|

)

(

) (

|

)

(
) is the fraction of people who benefit from the drug. However, the drug
where
only harms patients among whom it is contraindicated if doctors give those patients the drug.
The problem is that the FDA’s average-effects rule mathematically assumes this occurs, i.e., that
doctors give the drug to every patient even if it harms those patients. If the FDA had more faith
in doctors, it would instead estimate the value of a drug solely by its positive effects among the
subgroup that benefits from the drug.41 The FDA would not have to worry about harming
patients for whom the drug is inappropriate because doctors would not give these patients the
drug.

37

See Maggioni et al., supra note 31, at 99.

38

The European Union’s Committee for Proprietary Medicinal Products (CPMP) has a similar policy. Id. at 97.

39

See Richard Wunderink et al., FDA Evaluation of Antimicrobials: Subgroup Analysis, Letter to Editor, 126(6)
Chest 2300 (June 2005) (highlighting asymmetric implications of post hoc subgroup analysis for FDA approval).
40

See Anup Malani and Feifang Hu, The option value of new therapeutics 14, unpublished manuscript (2004). The
bad matching may be because there is no way to determine which patients benefit and which do not, because doctors
cannot or do not distinguish between patients that benefit and those that do not, or because doctors give the drug to
patients that they know will not benefit from it.
41

This value is larger than the average effect of the drug in clinical trials. Because (
(
|
)
(
|
) (
) (
|
).
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|

)

,

2.

Cost and benefits from post hoc subgroup analysis

The FDA’s conservative position on post hoc subgroup analysis is based on concerns that
multiple testing creates a risk of spurious correlation, which can result in false positive drug
approvals.42 To illustrate, consider the following Statistics 101-type hypothetical. Suppose there
is a population that can be divided into 10 mutually exclusive subgroups. For example, if the
trial population ranges in age uniformly from 20 to 70, we can divide the group into 10 equally
sized five-year age bins: 20-24, 25-39, etc. Suppose also that there is a drug which has no effect
on either the full population or on any subgroup, though there is some random variation in
observed outcomes either due to the drug or natural progression. For example, we might assume
that the treatment effect for each subgroup is a normally distributed random variable with mean
equal to zero and variance equal to one. The probability that the drug will be proven effective on
the full population with a confidence level of 95% is just 5%.
But if the sponsor seeking approval for our hypothetical drug is permitted to separately
test the drug against each of the 10 subgroups, the probability that he will be able to demonstrate
efficacy for at least one subgroup is 0.4 (= 1 – 0.9510). This obviously raises the risk of false
positives, that is, the possibility of approving the drug even though it has not been demonstrated
effective at the 95% confidence level.
If the FDA knows that the sponsor will test the drug against 10 subgroups, it can
implement a multiple testing correction or penalty to eliminate spurious results. For example, if
the outcomes in the 10 subgroups are known to be uncorrelated, then it can change the threshold
p-value required for approval from p = 0.05 to p = 0.05 / (number of tests) or 0.005.43 This
correction is known as the Bonferroni adjustment. It ensures the probability of observing even
one subgroup with significant treatment effects is back to 5%. The proper p-value adjustment in
the cases where outcomes in the subgroups are correlated is different, but this correlation and the
adjustment may be derived from the data.44
The problem is that the FDA does not know the number of subgroups against which the
sponsor will test its drug and cannot trust drug companies to honestly report this number.
Therefore, the FDA cannot in practice impose a proper multiple testing penalty. This problem
becomes exponentially more severe the larger the number of possible subgroups. Suppose the
sponsor can also divide the adult population by gender (male/female) and by ethnicity
42

See Kulynych, supra note 21, at 141, John A. Lewis, Statistical Issues in the Regulation of Medicine, 14 Stat. in
Med. 127, 132 (1995).
43

We are ignoring the 11th test on the full population to keep the numbers simple and because the full population
result is positively correlated with each subgroup result.
44

Sandrine Dudoit and Mark van der Laan, Multiple testing procedures with applications to genomics (New York:
Springer, 2008). See also the discussion in note 26.
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(white/black/Hispanic/other) and the drug still has no treatment effect for any subgroup. Now
the available subgroups has jumped from 10 based solely on age to 80 (= 10 × 2 × 4) based on a
combination of age, gender and ethnicity. If the sponsor can cherry-pick a subgroup in which to
demonstrate efficacy, the probability it will be find able to find at least one with a p-value less
than 0.05 is 0.98 (= 1 – 0.9580)! The sponsor has a strong financial incentive to cherry-pick in
this manner because the alternative may be not to obtain any return on its investment in the drug.
We call this the problem of opportunistic behavior by sponsors.45
The FDA’s response to this risk is to base its drug approval decision solely on average
treatment effects for the full trial population. This bars any approval based on post hoc subgroup
analysis without further clinical trials. But this response swings the pendulum of error too far in
the opposite direction. Instead of approving some drugs with no treatment effect (false
positives), the FDA’s conservative policy rejects some drugs with positive treatment effects for
some subgroups (false negatives) or increases the costs of drugs if the sponsor conducts a followon trial to confirm the results of post hoc subgroup analysis. To illustrate the problem of false
negatives, suppose that the drug in our hypothetical actually has positive treatment effects in one
of the 10 subgroups defined by age. The probability of approving the drug based on the results
for the full trial population is virtually zero.46
Before we can suggest a compromise solution, a good question to ask is whether post hoc
subgroup analysis can ever provide sufficiently reliable information to warrant approval of a
drug, even ignoring the risks from spurious correlation and opportunistic behavior. After all,
when subgroups are not specified before a trial begins, the trial is not powered – i.e., does not
have sufficient sample size and thus does not generate sufficient statistical information – to
estimate subgroup effects in a manner that meets the usual standards for confidence (5%) and
power (20%).47 Compounding this problem is that subgroups by definition have smaller sample
size than the full trial population.
45

We do not dispute that ex ante drug sponsors have an incentive to produce drugs that actually work. Productive
drugs surely generate more revenue than unproductive ones. The problem is post hoc subgroup analysis we examine
occurs after a drug sponsor has found that the average patient does not benefit from its drug. Therefore it is facing a
loss equal to the cost of its drug development expenses. The only reason it has to avoid spurious correlation due to
multiple testing is litigation risk from failure-to-warn products liability suits. But these suits can be foreclosed by
appropriate warnings. Moreover, they do not cover the risk of a drug being less effective than alternative treatment.
Finally, it is unlikely that the average ineffective drug has expected litigation costs larger than the incurred cost of
development.
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We do not think, however, that these concerns render post hoc analysis useless. There
are a number of technical reasons why such analysis may yield useful information even without a
larger sample. First, sample size calculations are based on estimates of the variance of treatment
effects in the full trial population. Because those estimates themselves have sample variation,
there is a positive probability that they are in fact too high, leaving samples larger than required
for accurate identification of subgroup effects. Second, because subgroups are a subset of the
full trial population, they are correlated with that population. Thus analysis of the full trial
population and one subgroup requires something less than a two-fold overestimate of variance to
be powered to give reliable information. Third, because subgroups may be more homogenous
than the full trial population, the subgroup may have smaller variation in treatment effects. This
diminished variation means that doubling the number of subgroups does not double the required
sample size for the trial. We shall demonstrate this in our analysis of the MGd trial.
3.

Rehabilitating post hoc subgroup analysis

In this section we discuss two proposals that offer a compromise between (1) false
positives due to opportunistic behavior and (2) false negatives or the cost of additional trials due
to the FDA’s cautious approach to subgroup analysis. Our aim is to extract more reliable
information on subgroup effects from trial data that can be used to approve drugs for use in
subgroups with as little additional cost as possible from larger sample size in the initial trial or a
new trial.
Our first proposal – the use of adaptive designs – should not come as a surprise. It has
been advocated by biostatisticians and regulators as a way to reduce sample size or limit harm to
trial participants even in the absence of varying treatment effects across patient subgroups.48 The
remainder of this section sketches how adaptive designs help address subgroup effects and
discuss the sample size costs of those designs. The second proposal – deferred to the next
section – requires a modified form of subgroup analysis to be performed by an outside
consultant. It would also allow the FDA to approve a drug without the expense of further trials.
a.

What the FDA should continue to do

Before explaining our reform proposals, we want to highlight two things that the FDA
gets right in its current policy towards subgroup analysis.49 First, the FDA is correct that, if the
48

See, e.g., Donald A. Berry, Bayesian clinical trials, 5 Nature Reviews - Drug Discovery 27 (2006) (arguing that
adaptive design can be employed to lower sample size and improve treatment outcomes for enrolled patients); Scott
Gottlieb, Speech before 2006 Conference on Adaptive Trial Design, Washington, DC (July 10, 2006), available at
http://www.fda.gov/oc/speeches/2006/trialdesign0710.html (last visited Jan. 28, 2009) (observing that adaptive
designs can ends trials of drugs with severe side effects more quickly).
49

However, we are concerned that the FDA makes other mistakes when aggregating information across clinical
trials. Although the FDA may correctly apply multiple-testing corrections within trials, there is reason to be
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identity of sensitive subgroups is known prior to a trial, the sponsor should set the sample size
for a trial so that the trial is able to estimate significant results for these subgroups.50 For reasons
mentioned earlier (correlation between subgroup outcomes and full trial population outcomes
and greater homogeneity within subgroups), the additional sample size required to analyze two
subgroups is not double that required to analyze the single full trial population. Therefore, the
costs of powering a trial to test a priori specified subgroups is less than proportional to the
number of groups, as is often assumed.
Second, the FDA is also correct to use multiple-testing adjustments to avoid spurious
results from analysis of a priori specified subgroups. The FDA is aware that Bonferroni
adjustments may be too conservative because of the assumption that subgroups are independent.
Because some patients fall in multiple subgroups or share biological features of members in
other subgroups, treatment results in one subgroup may be related to effects in another subgroup.
Thus, separate tests on two subgroups are less than two bites at the apple. Applying a Bonferroni
adjustment in this case would result in an overcorrection for the risk of spurious correlation.
b.

Adaptive trials proposal
i.

Background on adaptive trials

concerned that the FDA does not apply those corrections correctly across trials. Suppose a sponsor conducts an
initial trial that does not show intent-to-treat effects but post hoc analysis reveals possible subgroup effects, and the
sponsor conducts a second trial solely to confirm the subgroup effects. One the one hand, the second trial should be
able to credit subgroup members in the first trial towards sample size requirements in the second trial. On the other
hand, a significant result in the second trial may be spurious because it is itself a second test. Indeed, if one
conducted 100 trials on a given subgroup, 5% would show significant effects for that subgroup even if its true effect
is zero. This risk of multiple testing across trials is partly addressed by the fact that a company must inform the
FDA of every trial it conducts to support an IND and by the fact that many journals will not publish an article
reporting the results of a trial that has not been reported to a trial registry such as clinicaltrials.gov. See 21 C.F.R. §
312.23 (2008); Catherine De Angelis, et al., Clinical trial registration: a statement from the International
Committee of Medical Journal Editors, 141 Ann. Intern. Med. 477 (2004). We cannot, however, find evidence from
stated FDA policy or practice that the FDA understands and properly addresses these concerns. That said, it is likely
the case that the extreme cost of Phase III trials limits the frequency of opportunistic behavior across multiple trials.
50

An even better approach may be to specify subgroups not by patient characteristics at baseline, but by an
algorithm that has as inputs not just those characteristics but also outcomes recorded as the trial progresses. Suppose
the sponsor suspects that treatment effects may depend on one of 10 genetic markers, but is not sure which one.
Instead of picking one of the those markers before the trial begins, the sponsor could, for example, specify that after
fraction of subjects have enrolled, it will correlate those markers with outcomes and pick as a subgroup those
subjects possessing the marker with the highest correlation with outcomes. So long as  is specified before the
trial begins, it is theoretically possible – though perhaps not easy – to derive a sample size to ensure this trial is
properly powered. There may not be any penalty for multiple testing so that the critical p-value may remain 0.05.
Nor is there a risk of opportunistic behavior by the sponsor since the FDA can implement the algorithm itself and
verify the subgroup the sponsor has identified as correct.
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The prototypical clinical trial is a fixed design trial. In this design, patients are
randomized between a treatment group and a control group. The total number of patients
enrolled in the trial – the sample size – and the fraction of patients assigned to treatment group
are fixed before the trial begins and remain the same until it ends. The sample size required to
run such a trial depends on the minimal size of clinically-relevant treatment effects the sponsor
wants to be able to identify and the variance
of the treatment effect from the drug.51
The problem is that the sponsor may not know these parameters. Indeed, one of the
purposes of the trial is to estimate these parameters. One solution is to use results from prior
studies of the sponsor’s drug or of related drugs. When such studies are not available or are
unreliable, the sponsor can use what is called an adaptive design trial. Such a trial begins
without firm or completely reliable estimates of the parameters above. Instead, the trial employs
real time data gathered from early-enrolling patients to refine estimates of the parameters and
adjust sample size or treatment allocation based on the new estimates.
There are two types of adaptive designs that use interim data to modify sample size while
the trial is in progress. In one, called a sequential-group approach, the sponsor starts with a trial
that is conservatively large – using parameters at the lower end of the range for clinicallyrelevant effects and at the higher end of the range for variation in treatment effects – but stops
the trial early if interim data suggest that treatment effects are larger than clinically relevant or
have smaller variance than hypothesized. The other design, called simply an adaptive approach,
does the opposite. It starts with a trial that is deliberately small and extends the trial if estimates
of the treatment effect are smaller than the clinically relevant amount or estimates of the
treatment effect variance are larger than hypothesized. Either adaptive design requires a larger
sample size than a fixed design. Moreover, because the trial is updated after the sponsor “tests”
the data by estimating treatment effects, the critical p-value may have to be reduced to account
for multiple testing. The exact multiple-testing penalty has been derived in statistical literature.52
There are also adaptive designs intended to adjust the proportion of enrolled subjects
assigned to the treatment group based on interim data analysis. If, for example, outcomes in the
treatment group show higher variance relative to the control group than anticipated, then the
sponsor may change group assignments so that more than half of subjects get treatment. So long
as the estimate of the variance of treatment effects – the difference in outcomes in the treatment
and control groups – does not increase, so that the sample size remains constant, the sponsor
pays no multiple-testing penalty for such an adaptive design.53
51
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Cyrus R. Mehta and Nitin R. Patel, Adaptive, Group Sequential and Decision Theoretic Approaches to Sample
Size Determination, 25 Statistics in Medicine 3250-3269 (2006).
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Even if the estimate of variance of treatment effects falls, the sponsor cannot stop the trial early. But if the
estimate of overall variance of treatment effects rises, then the sample size increases and the sponsor must pay a
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The FDA is open to use of adaptive designs. Its Critical Path initiative begun in 2004,
seeks to identify biological and statistical innovations that can improve the efficiency of clinical
trials and incorporate them into the drug development and approval process. That initiative has
identified adaptive designs as one area on which to focus its attention. Indeed, the FDA is
expected to release a guidance on adaptive designs to clarify its thinking.54
ii.

Adaptive design for subgroup analysis

None of these adaptive designs, however, are specifically intended to address subgroup
effects. They are mainly directed at optimizing over power and cost for main group effects.
That does not mean that that no one has thought of applying adaptive designs to estimate
subgroup effects. We know of no instances, however, where the FDA has approved an adaptive
design to facilitate subgroup analysis, though the FDA has considered or allowed a number of
trials with adaptive designs.
How might an adaptive design be used for subgroup analysis? Consider a two-arm trial
(treatment and control)55 with sample size set to test just one hypothesis: the average treatment
effect for one all enrolled patients is zero. At some interim point, the sponsor or the independent
data monitoring committee (IDMC) examines the data to determine if there is a subgroup of
patients on which the trial should focus because they may be particularly responsive to treatment.
There are two types of data that might be used to identify subgroups: baseline characteristics
measured before the start of a trial alone or treatment outcomes measured during the course of
the trial. In the first case, the sponsor looks for abnormal variation in a relevant covariate. For
example, if there is much more variation than expected in treatment history or in the pre-trial
progression of symptoms, the full trial population can be divided into subgroups using a cut-off
based on the extent of prior treatment or symptoms. In the second case, the IDMC may look at
the relationship between certain covariates and treatment effects. (The IDMC is used rather than
the sponsor to ensure that the sponsor does not become unblinded.) If the data suggests, for
example, that certain age or ethnic subpopulations are responding better to treatment, those
groups can become target subgroups for the study.
After this interim analysis, the sponsor would have to revisit the objective of the trial.
There are two choices. First, the sponsor could examine just one hypothesis but limit it to a
subgroup identified by interim analysis as particularly sensitive to treatment. Specifically, the
null hypothesis would become: the treatment effect for one subgroup is zero. We assume in this
case that, after the interim analysis, the sponsor would discontinue enrollment of subjects that do
multiple-testing penalty. The reason is that it was given a “real option” of testing and must pay a price for this
option.
54

See Gottlieb, supra note 48.
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This is also called a parallel-armed trial.
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not belong to this subgroup, lest they waste sample size. The sponsor’s other choice is to
examine two or more hypotheses based on the number of subgroups discovered through interim
analysis. For example, if that analysis identified two subgroups based on ethnicity, the trial
might test two hypotheses: the treatment effect for whites is zero and the treatment effect for
non-whites is zero.
As with adaptive designs targeting sample size adjustments, adaptive designs targeting
subgroups will require a larger sample size and appropriate adjustments of the statistical
methodology. These can be derived, though we do not do so here. In particular, the design may
require that that the sponsor pay a penalty, i.e., that the results be held to a more stringent or
lower critical p-value before they are declared statistically significant, to account for the
possibility of multiple testing. We explore these penalties in the Appendix.
Before we conclude our discussion of adaptive designs, it is worth noting an important
weakness of these designs. Because of ethical and profit considerations, they may not be optimal
for identifying side effects of treatments. If interim analysis suggests a particular subgroup may
have worse side effects, both the sponsor and patient advocates will push to exclude that
subgroup from further analysis. But doing so limits the amount of data we have on that subgroup
and thus on the side effects of the drug.
c.

Proposal for independent post hoc subgroup analysis

In this subsection we consider how it might be possible – working with a fixed, nonadaptive design trial – to use post hoc subgroup analysis to approve a drug without further trials.
Post hoc subgroup analysis does not increase the risk of false positive drug approvals so long as
the FDA makes appropriate multiple-testing corrections. But appropriate multiple-testing
corrections require knowledge of the number of tests the sponsor has performed. Because of the
financial incentive to have its drug approved, the sponsor cannot be relied upon to truthfully
report the number of tests it has performed.56 Indeed, the FDA can be confident that the sponsor
probably conducted more tests than that for which the FDA plans to adjust. Therefore, there
remains a residual risk of false positive above 5%.
i.

Choosing an independent agent

56

We have considered the possibility that the FDA could specify prior to a phase III trial the exact subgroups the
sponsor may examine. This could be based on the subject-matter of the trial or on the FDA’s knowledge of data
from trials of competing drugs by other sponsors. There are two problems with this reform. First, the sponsor could
specify subgroups based on subject matter as well as the FDA and has a strong financial interest in doing so. We
doubt there are valuable subgroups that the FDA could propose that the sponsor will not have already considered.
Second, sponsors of the competing drugs are likely to object to the FDA’s use of their trial data – which is treated as
a trade secret, see Article 39.3 of the Trade-Related Intellectual Property (TRIPs) agreement – in this manner. They
would have a reasonable argument that this competitively favors later new drug applicants over earlier ones. It
would also subtly reduce the incentive to innovate quickly.
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A critical assumption in this logic is that the sponsor is financially interested in having
the drug approved. If post hoc subgroup analysis were performed by a truly independent auditor,
then the FDA could rely upon that agent’s report of the number of tests it conducted and fully
eliminate the risk of false positives by means of multiple-testing adjustments. Of course the real
question is whether the auditor is truly independent, a topic to which we will turn in a moment.
There are two basic candidates for an independent auditor: the FDA and an outside
statistical consulting firm. Each has its strengths and weaknesses. The strength of using the
FDA is that by doing the post hoc subgroup analysis itself, the FDA knows immediately the
number of tests conducted. There is no need to rely on the absence of any other motive, as will
be the case with an outside consulting firm. There are two weaknesses of the FDA. It has
limited resources that make it difficult to maintain even the current level of scrutiny of new drug
applications (NDAs).57 Moreover, the FDA is subject to political pressure. It has been criticized
for being influenced both by drug companies and by political backlash following approval of
unsafe drugs.58 These pressures are unlikely to perfectly offset to create an unbiased
decisionmaker. As a result, the FDA may conduct too much subgroup analysis – at the cost of
false positives – or too little subgroup analysis – at the cost of false negatives or more costly
approval.
The alternative is an outside statistical consulting firm. Many already exist to help
sponsors design and analyze data from trials.59 The strength of consulting firms is, perhaps,
more statistical expertise than the FDA. Unlike the FDA, which has limited resources and no
need to compete, these firms have every reason to specialize and innovate because it may make it
more likely they are selected to perform subgroup analysis.
The main weakness of the consulting firm approach is that these firms may not be truly
independent. Sponsors are repeat players. A consulting firm may have an incentive to give a
favorable analysis so as to secure repeat business from sponsors. That repeat business may be
for subgroup analysis or some other statistical service. This is a lesson well learned from the
corporate accounting scandals from earlier this decade.60 Perhaps the indirect influence of
57

See, e.g., Institute of Medicine, The Future of Drug Safety: Promoting and Protecting the Health of the Public
193 (2007). Drawing inspiration from PDUFA, one possible solution is to charge companies that seek drug
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sponsors can be addressed by requiring the FDA to select the outside consultant to perform post
hoc analysis, by blinding the sponsor to the outside firm selected, and by banning firms that
perform post hoc analysis from providing other statistical services to sponsors. We wonder,
however, whether the agency will always be able to keep the identity of the consulting firm
secret, even after the analysis is completed and the FDA has made its regulatory decision
concerning a sponsor’s drug. Moreover, restricting the consulting firms’ scope of business will
limit their ability to attract talent and incentive to innovate in the area of subgroup analysis since
it comes at the cost of other lines of business.
A second weakness of using consulting firms is that “independence of the sponsor” is not
the same thing as “motivated to reduce false positives.” True independence only guarantees the
consulting firm will not be swayed by the profit interests of the sponsor. It does not guarantee
that the consulting firm extracts the most and reliable data from post hoc analysis after it is
chosen to perform that analysis. This problem is one which economists call moral hazard.
Independence merely substitutes the sponsor’s interests with those of the consulting firm. Most
likely this is cost minimization, which may imply too many false negatives or false positives,
whichever minimize the consulting firm’s labor expense.61
ii.

Statistical methods to guarantee independence

To address the problem that neither the FDA nor the outside consultant may be truly
independent of the sponsor, we propose two statistical methods to limit either agent’s ability to
skew the analysis in favor of the sponsor.62 For convenience, we shall speak as if the consulting
firm has been chosen to conduct the analysis.
No-outcome data analysis. The first approach would provide the consultant with all the
data from the trial except variables that identify treatment assignments and health outcomes and
61

The outside consulting firm must also be concerned about not doing too many tests. Each useless test it performs
increases the multiple-testing adjustment for any positive finding. Minimizing false negatives requires internalizing
this negative externality. Since false negatives are unobservable, the FDA cannot directly incentivize the consulting
firm to do so. And the FDA certainly should not give the firm an incentive keyed to drug approval, because then it
would have incentives like the sponsor and replace false negatives with false positives.
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These methods do not address other problems, such as the limited resources of the FDA or the insufficient
motivation of outside consulting firms. If the statistical methods we discuss help ensure that the consultant truly
cannot manipulate the data to increase false positives, then one might address the problem of a consultant’s
motivation by giving it stock in the sponsor. (This is identical to extracting the outcome or a random subsample of
data from the data archives of the drug sponsor. We consider granting the consultant stock instead because it is
virtually impossible to separate the sponsor from knowledge of its data.) We do not advocate this because it is too
radical and would be politically infeasible. That said, giving the consultant some sponsor stock is not the same as
allowing the sponsor to conduct the entire post hoc subgroup analysis because the statistical methods we propose in
the main text require that the consultant not have access to certain data that the sponsor already has, or could easily
obtain.
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ask it to identify subgroups based on baseline characteristics that exhibit “remarkable and
relevant variation” in the trial data.63 (This is similar to one of the approaches used to identify
subgroups for the adaptive design trials discussed in the last subsection.) The consultant would
not be asked to perform the post hoc subgroup analysis; that could be conducted by the sponsor,
though the FDA would rely upon positive treatment effects only for the subgroups identified by
the consultant. Whatever positive subgroup results the sponsor reports, the FDA would apply a
multiple-testing adjustment based on all the subgroups reported by the outside consultant.
In order to identify remarkable variation, the consultant needs to have a sense of what
normal variation would be. It could estimate normal variation in baseline characteristics from
trials of the sponsor’s drug or prior studies in the literature. The consultant would have to be
sensitive to exclusion and inclusion criteria, which can affect the applicability of prior data to the
current trial sample. Moreover, the consultant would have to keep in mind that any subgroup it
identifies should be defined by variables that are plausibly relevant (from our current biological
understanding of the disease targeted by the sponsor’s drug and the pharmacology of that drug)
to the treatment effects of the drug.
Split-sample analysis. The second statistical method we propose to ensure that the
consultant’s choice of subgroups is not influenced by the rug company requires splitting the data
from a trial into two parts. One part would be called the exploratory subsample and the other
part the confirmatory subsample. Importantly, the FDA must split the sample to ensure the drug
company has no influence and the sample should be split randomly to ensure the samples are
statistically independent. The consultant would only be given the exploratory subsample and be
asked to conduct a full post hoc subgroup analysis on that subsample to identify subgroups that
respond better to the drug.64 The sponsor would then be allowed to perform post hoc subgroup
analysis on the confirmatory sample using only the subgroups identified from the exploratory
subsample by the consultant. As before, the FDA would apply a multiple-testing penalty based
on all the subgroups reported by the outside consultant. If, after such penalty, the confirmatory
subsample validates the positive subgroup effects from the exploratory subsample, the FDA
could approve the drug only for those subgroups.
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While we focus on identifying subgroups by examining baseline characteristics with remarkable variation, it is
equally valid to ask the consultant to identify subgroups by examining baseline characteristics which have a
distribution which is remarkable in any significant way. This instruction would allow subgroups to be identified by
characteristics with, for example, surprising high or low means or skew. The statistical method we present in the
main text focuses on the second moment of the baseline characteristic only for purposes of illustration.
64

The sponsor could not be asked to do this because it would likely be able to derive the confirmatory subsample
from the exploratory subsample and the full sample, which it already possesses. This would allow it to choose
subgroups ostensibly on the exploratory subsample but truly on the full sample. The result would be almost the
same as post hoc subgroup analysis by the sponsor.
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Both statistical methods ensure that subgroups are identified independent of the interests
of the sponsor. Since the first method does not give the consultant access to outcome data, it
cannot choose subgroups to help or hinder the sponsor. Since the second method requires the
sponsor to limit its subgroup analysis to a subsample that is statistically independent of the
subsample analyzed by the consultant, the consultant’s analysis cannot help the sponsor engage
in data mining. Moreover, neither method requires that the FDA impose any additional
multiple-testing penalty beyond one based on the total number of subgroups identified by the
consultant.
Each statistical method also has its shortcomings. The weakness of the no-outcome data
approach is that the subgroups with the most remarkable variation may not be perfectly
correlated with the subgroups that have positive and significant treatment effects. Abnormal
variation is just one factor that suggests differential treatment effects; it does not guarantee them.
The main concern with split-sample approach is that the post hoc subgroup analysis, which
would be underpowered even if performed on the whole trial sample, is particularly
underpowered if performed on subsamples. This will increase the risk of false negatives. This
risk may be considered the cost of independence under this method. In short, the two statistical
algorithms reduce, but do not eliminate false negatives.
4.

An illustration with motexafin gadolinium

In this section we illustrate our two statistical algorithms for ensuring independent post
hoc subgroup analysis by applying them to a real world example: motexafin gandolium (MGd)
for patients with brain metastases from solid lung tumor. MGd is sponsored by Pharmacyclics
(ticker PYCY), a small biotech company that branded the drug as Xcytrin. We first provide
some background on clinical testing of the drug and then discuss post hoc subgroup analysis of
the testing results.
a.

Background on MGd

Tumorous cancers in one part of the body often spread – or metastasize – to other parts of
the body. In up to 24% of all cancer patients, they spread to the brain.65 The risk is especially
severe with lung cancer, where up to 50% of patients experience brain metastasis66 and
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J.B. Posner, Neurological complications of cancer (1995).
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M. Stuschke, W. Eberhardt, C. Pottgen, et al., Prophylactic cranial irradiation in locally advanced non-small-cell
lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuropsychological
effects, 17 J. Clin. Oncol. 2700-2709 (1999); T.J. Robnett, M. Machtay, J.P. Stevenson, et al., Factor affecting the
risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma, 19 J.
Clin. Oncol. 1344-1349 (2001).
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metastasis occurs earlier than with other cancers.67 Most patients with brain metastases die.
Median survival on whole brain radiation therapy, the typical conventional treatment, is only 4
months. For those who do manage to survive, however, there is a major risk of neurological
impairment.68
MGd is a drug that demonstrated the ability to increase the radiation response of tumor
cells in preclinical studies. Pharmacyclics sought to market the drug as a treatment for brain
metastases. The company filed an investigational new drug (IND) application with the FDA to
begin clinical testing of the drug in human patients. After a successful Phase I/II study,69 the
company began a Phase III study (called trial 9801) that enrolled patients with any type of
cancerous tumor who developed brain metastases. Subjects were randomized to either whole
brain radiation therapy (WBRT) alone (the control arm) or MGd and WBRT (treatment arm).
Unfortunately, this study did not find a statistically significant treatment effect with respect to
median survival or time to neurological impairment.70
One bright spot in trial 9801, however, was that patients with specifically lung cancer did
experience statistically significant extension of time to neurological impairment.71 So
Pharmacyclics conducted a second Phase III trial (called Trial 0211) targeting only lung cancer
patients. Unfortunately, this second trial was unable to validate the results from the initial trial.
This is illustrated in Table 2, which summarizes the results from trial 0211 and from lung cancer
patients in trial 9801. According to the first panel, whereas the relative hazard rate for
neurological impairment72 was 0.61 (p = 0.05) in the initial trial, it was merely 0.78 and not
significantly different from 1 (p = 0.1) in the second trial.
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median patient on WBRT alone experienced impairment at 7.4 mo (p = 0.048). Mehta et al., supra note 68, at 2533
(Fig. 2, panel C).
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Neurological impairment was judged by a battery of standardized neurocognitive tests. The tests were scored by
blinded graders. Patients were said to be impaired if the composite score was at least 1.5 standard deviations worse
than the mean of the test’s age-adjusted distribution. Christina A. Meyers, et al., Neurocognitive Function and
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Trying to explain the discrepancy between the trials and to salvage MGd for a new drug
application (NDA), Pharmacyclics conducted a post hoc subgroup analysis. According to the
company, this analysis revealed a problem at some of the study centers in France. Although the
trial protocol required that subjects be randomized to treatment as soon as they were diagnosed
with brain metastases, the French centers waited several weeks or more after diagnosis before
randomizing subjects to treatment.73 In the interim, the centers gave subjects chemotherapy74
(hence these subjects are labeled “controlled” patients in the data). Moreover, subjects were
ultimately randomized in trial 0211 only if their brain tumors progressed despite chemotherapy,
i.e., their tumors were resistant to treatment.75 So this was a self-selected group of tumors.
Whereas “uncontrolled” subjects randomized immediately had a mix of resistant and nonresistant brain tumors, the controlled subjects ultimately randomized in the problematic French
centers largely had tumors resistant to WBRT. This placed MGd at a disadvantage in these
centers.76
Not surprisingly, these subjects also did not show benefit from MGd. Excluding these
late-randomizing centers from the analysis revealed that drug had a statistically significant effect
on delay until onset of neurological impairment. As reported in the second of panel of Table 2,
Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium:
Results of a Randomized Phase III Trial, 22 J. Clin. Oncology 157, 158 (2004). The hazard rate for impairment is
the rate at which patients are judged impaired, i.e., it is the fraction of additional patients judged impaired each
month. The relative hazard rate is the ratio of the hazard rate in the treatment group to the rate in the control group.
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Ordinarily, a drug sponsor is responsible for ensuring that its study centers follow trial protocols. The company
attributes the problem in this case to recruitment difficulties. Whereas the trial 9801 had 401 total patients, of which
only 251 had lung cancer, trial 0211 required 554 lung cancer patients to have the statistical power to validate the
positive results for lung cancer patients from the initial trial. This required the second trial to recruit patients from
90 treatment centers throughout the world, more than double the 40 centers involved in the initial Phase III trial.
The company argues that it is difficult to precisely enforce the protocol with so many centers involved in a study.
Personal communication with Richard Miller, former CEO of Pharmacyclics, Mar. 14, 2008.
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Chemotherapy is not thought to be a reliable treatment for brain metastases because chemotherapy relies upon
drug delivered by blood and the brain tumor is somewhat protected from chemotherapy drugs by the blood-brain
barrier.
75

The implicit but reasonable assumption here is that a brain tumor resistant to chemotherapy is resistant to any
other form of treatment.
76

The selection story is a bit more complicated. The delay also screened out patients who had died from, inter alia,
the brain metastases prior to randomization. Since early death is an indicator of a more severe brain tumor, this
mortality screen likely selected for less severe brain tumors. It is probably the case that the selection on the basis of
resistance to chemotherapy (which likely reduced the effect of MGd) was more significant than selection based on
survival (which possibly increased the effect of MGd). The reason is that median survival following diagnosis with
brain metastases is 4 months, so it is unlikely that mortality was a material screen in the first two weeks following
diagnosis. Yet it is in these first two weeks that the company found a significant delay in neurological impairment
among patients treated with MGd.
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the relative hazard rate for uncontrolled subjects on MGd in the 0211 trial was 0.56 (p = 0.02).
In other words, while MGd proved effective among subjects with uncontrolled brain tumor, this
effect was masked by including subjects with controlled brain tumor in the main analysis.
Pharmacyclics filed an NDA with the FDA relying on this subgroup analysis. But the FDA did
not credit the company’s explanation and finally rejected its NDA in December 2007.77
Of course, this is the company’s explanation for its unsuccessful final Phase III trial and
it had a financial stake in getting MGd approved for some subgroup. Our aim is to scrutinize
these claims by taking the role of an outside consultant and checking whether analysis of data in
a manner that is independent of the financial interests of the sponsor identifies the same sensitive
subgroups that the sponsor identified, namely the subjects with uncontrolled tumor.
b.

No-outcome data analysis

Our first analysis examines the final Phase III study (trial 0211) data stripped of outcome
variables. The idea is that an independent statistical consultant without outcome data would not
be able to select subgroups that would financially benefit the company because it does not know
whether any subgroups had better or worse outcomes than average among the full trial
population. Instead, this consultant would identify subgroups by searching for baseline
characteristics on which current trial subjects had excess variation relative subjects in previous
trials or in the population. These characteristics could then be used to define subgroups on
which the drug company could perform post hoc subgroup analysis. If and only if that subgroup
analysis suggested the subgroup responded positively to the drug, the FDA should approve the
drug for use in that subgroup.
To implement this algorithm, we compare the variation of certain medical characteristics
in the trial 0211 sample with variation of those variables in the initial Phase III study (trial 9801)
sample. The variables include features of the primary (lung) tumor, treatment of the primary
tumor, features of the brain metastases, the treatment of the brain metastases before enrollment,
and neurological impairment at baseline. Table 3 reports the ratio of variances of each variable
across the two samples and the p-value for the hypothesis test that the variances are equal across
the samples after adjusting for multiple testing.
Eight subgroups stand out. The 0211 trial had excess variation in the variables: days
from diagnosis of brain metastases to randomization, extracranial metastases, baseline Trail B
score, and whether the study center was in Canada. The delay variable captures some of the
company’s concern that patients in some French centers received chemotherapy for a few weeks
before being randomized and that the brain masses that survived this chemotherapy were more
resilient. The trail B is a test of cognitive ability where the subject is asked to follow a “trail” on
77

See supra note 23.
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a sheet of paper with his pencil. A lower score is better: it indicates less time was required to
follow the trail. It also indicates that the brain metastasis probably has not advanced beyond the
point where it can be treated.
The 0211 trial also had insufficient variation in: primary tumor (PT) resected without
recurrence, primary tumor is large cell carcinoma, primary tumor controlled, and study center is
in the US. The PT resected variable is one of five categories into which a primary tumor is
categorized at the time a patient is randomized.78 The resected category indicates that the
primary tumor was surgically and successfully treated and the patients only remaining concern is
the brain metastases. The PT controlled variable is the complement of the variable that the
company identified as being responsible for the failure of the 0211 trial.
Having identified eight subgroups with remarkable variation, we now check to see if
MGd was particularly effective amongst these subgroups in the full 0211 data. For binary
variables, subgroups are defined by their two states. For continuous variables subgroups in the
0211 data are defined by whether a characteristic lies above or below the median for that
characteristic in the 9801 data. Table 4 summarizes our subgroup analyses with a multipletesting adjustment that accounts for 16 tests (eight variables with excess variation and two
subgroups for each variable). We find four subgroups have significant treatment effects, i.e.,
lower rate of neurological impairment: subjects with little delay before randomization, subjects
at U.S. study centers, subjects with low (good) baseline Trail B scores, and subjects with
uncontrolled brain metastases.
Thus the no-outcome data analysis would support Pharmacyclics’ case for approval for
subjects with uncontrolled brain tumors. The other subgroups that survive no-outcome data
analysis are consistent with the company’s theory that MGd works on less resistant tumors.
Subjects randomized quickly and subjects in the U.S. are less likely to have received
chemotherapy before randomization. As for subjects with low trail B scores, these are subjects
whose tumors are not so far along that they already seriously impede subjects’ cognitive
capacity. It makes sense the treatment is also likely to work in these cases.
c. Split-sample analysis
Our second (and preferred) proposal is to split the data from trial 0211 into two
subsamples, have an outside consultant to identify subgroups via post hoc subgroup analysis on
one (exploratory) sample, and then allow the drug sponsor to validate significant treatment
effects for the other (confirmatory) sample. Only if a subgroup identified by the outside
78

The tumor may have been (1) “newly diagnosed,” which means the primary tumor and the brain metastasis was
diagnosed at the same time, (2) surgically removed or resected without recurrence, (3) treated for less than 4 weeks
without clear indication that it has progressed, (4) treated for greater than 4 weeks with no sign of progression, or (5)
treated for any amount of time with evidence of progression.
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consultant demonstrates statistically significant effects – after a multiple-testing penalty – in the
confirmatory sample should the FDA approve the drug for that subgroup. Because the outside
consultant does not have access to the confirmatory sample and because the FDA would only
credit evidence of treatment effects from the confirmatory subsample, the consultant cannot rig
its analysis to help the drug sponsor.
We begin our simulation of the split-sample analysis by randomly dividing the 0211 trial
sample into a 20% exploratory sample and an 80% confirmatory sample.79 The second step is to
conduct a subgroup analysis of the exploratory sample where subgroups are defined according to
baseline variables. The results of this analysis are presented in Table 5. The vertical panel
labeled “Value A” gives the relative hazard of neurological impairment and the p-value for each
variable at value 0 for binary variables and at the first quartile for continuous variables. The
vertical panel labeled “Value B” gives the relative hazard of neurological impairment and the pvalue for each variable at value 1 for binary variables and at the third quartile for continuous
variables.80 None of the p-values have been adjusted for multiple testing.81 We choose a
subgroup (now defined both by a given variable and a specific value for that variable) for the
third step in our simulation if it has a p-value less than 0.05, i.e., if we can be 95% confident that
the membership in the subgroup improves treatment effects. The two subgroups we identify in
this manner are (1) enrollment at center other than one in France and (2) not having previously
received the chemotherapy drug carboplatin. The relative hazard rate (into neurological
impairment) for subjects outside France and on MGd is 0.32 (p = 0.05363) and for subjects not
having received carboplatin and on MGD is 0.039 (p = 0.07833).
The last step in the split sample analysis is to estimate the treatment effects for these
subgroups in the confirmatory sample. This analysis reveals that the relative hazard rate for
MGd among subjects outside France is 0.676 (raw p = 0.038, adj. p = 0.076) and among subjects
who had not previously been treated with carboplatin is 0.905 (raw p = 0.58, adj. p = 0.58).
Even with the high correlation ( = 0.39) in membership across these subgroups, the effect of
MGd outside France is not statistically significant after adjusting p-values for multiple tests (on
two groups). The effect of type of prior chemotherapy is not significant even without the
multiple-testing adjustment.
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Our selection of a 20-80 split is arbitrary. Further statistical analysis is required to determine the optimal split of
the sample. The larger is the exploratory sample, the greater is the probability of identifying a subgroup that
benefits but the smaller is the probability that one will be able to confirm that it benefits.
80

The first two columns of data present the ratio of relative hazards among the two subgroups defined for each
variable and the p-value for this ratio.
81

No multiple testing penalty is required when analyzing the exploratory sample. The only purpose in that sample
is to identify certain subgroups, relative to other subgroups, that have a better response. Moreover, the size of the
exploratory sample is too small to pass any of the usual statistical tests (e.g., p = 0.05), let alone ones that adjust for
spurious correlation from multiple testing.
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So it appears that our spit sample analysis – unlike the no-outcome data analysis – fails to
support Pharmacyclics explanation for why the 0211 trial did not validate the 9801 trial. To be
precise, however, all we have shown is that the particular sample split we randomly drew chose
did not validate Pharmacyclics claim. Perhaps another random split would validate their claim.
Indeed, a better way to characterize the value of the split-sample analysis for eliminating alleged
false negatives is to ask, what fraction of splits would validate Pharmacyclics’ claim that MGd
works in the subgroup of patients whose brain tumor was not controlled via chemotherapy?
To conduct this analysis we drew 100 splits of the 0211 trial data and ranked the
subgroups in the exploratory stage in order of statistical significance of relative hazard for
neurological impairment, just as Table 5 did for our initial split. The first row of Table 6
provides the distribution of p-values that the “uncontrolled” subgroup takes across the hundred
splits, with a smaller p-value indicating a larger significance of that difference. We find that in
35% of draws uncontrolled has a p-value of less than 0.05. Thus in 35% of cases, the
“uncontrolled” subgroup advances to the validation stage. Further, in 31% (= 11/35) of these
cases, the effect among the uncontrolled subgroup is validated in the confirmatory sample after a
conservative Bonferroni multiple-testing adjustment that accounts for the number of subgroups
that emerge from the exploratory analysis in each sample split. See row 3 of Table 6. In other
words, in only 11 % of cases, the split-sample analysis confirms Pharmacyclics’ claim that MGd
works so long as the patient’s brain tumor is not previously treated with chemotherapy.
Because in the case of MGd we have not one but two Phase III trials, there is one other
test we can do – in the spirit of split sample analysis – to verify Pharmacyclics’ claim about
uncontrolled patients. We can check whether the subgroup effects identified by the company, by
the no-outcome data analysis, and by 11 % of the split-sample analyses above can be validated
by in the subsample of lung cancer patients in the 9801 trial.82 As can be seen in Table 2, the
uncontrolled subgroup is indeed associated with statistically significant treatment effect (RH =
0.48, p = 0.03).
Conclusion
Roughly one in five drugs that enter clinical testing fails to prove that it is effective and
safe. Even in phase III, the failure rate is 36%.83 Sometimes failure is just that: the drug has no
value. But other times a drug is right for some patients and wrong for others. Denying approval
for a drug that benefits some patients, but not the average patient, increases the costs of drug
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Indeed, we could ask the same thing of any subgroup identified by the no-outcome data analysis or the splitsample analysis that was verified in the 0211 analysis. Though we would then have to apply a multiple-testing
adjustment accounting for all the groups we test. Since only uncontrolled survives our 0211 validation, that is all we
test.
83

See Adams and Brantner, supra note 2, at 422 (Exhibit 1).
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development but not the benefits. Ideally, one would like to salvage such a drug by allowing its
use for the non-average patient who would benefit.
The challenge is bad behavior or moral hazard by drug sponsors. With post hoc subgroup
analysis (or data dredging in less polite language), sponsors will nearly always be able to find a
subgroup of patients who appear to benefit from a drug. Currently, the FDA addresses this risk
of spurious correlation by requiring sponsors to validate their findings with additional clinical
trials. But this may cost tens of millions of dollars, and in turn increase the price of drugs.
This paper offers a combination of institutional designs and statistical methods that can
limit the risk of spurious findings – or false positives – from post hoc subgroup analysis without
requiring additional, whole trials. Our proposal for adaptive trials allows the use of subgroups to
revise the hypothesis tests in a trial with little additional sample size. Our proposal for
independent statistical analysis, when combined with subgroup analysis without outcome data or
subgroup analysis validated on a split sample, can actually identify subgroups increasing the risk
of false positives or requiring additional sample size. In other words, our proposals offer an
approach to reduce the rate of failure in clinical trials, without a higher risk of false positives or
with minimal additional clinical testing costs.
While our proposals may be helpful, we recognize they are not panaceas. It is possible
that a drug which fails the average patient standard used by the FDA may not in fact be helpful
to any subgroup of patients. Our methods for identifying false negatives – drugs that have value
for a subgroup of patients but not the average patient – may not identify every false negative.
Finally, even if a drug is approved for the right subgroup, doctors may use it for the wrong
subgroups or use it off label. These are forms of false positives that we cannot address. Indeed,
by increasing the number of drugs available to doctors, we increase the risk of post-approval
false positives.
The reason we believe our proposals are worth pursuing, however, is that the alternatives
– using an average-patient standard or requiring additional trials – are worse. As we explained in
Section 1, the average-patient standard implicitly assumes that doctor always give the drug to the
wrong subgroup. While doctors may not be perfect at sorting patients to drugs, we do not
believe they are as bad as the FDA’s standard assumes. Moreover, trials – especially Phase III
trials – are very expensive.84 Trials focusing on subgroups are even more costly. Because fewer
patients are members of the subgroup than the full trial population, a trial focusing on a subgroup
will take longer complete recruitment. This, in turn, increases the opportunity costs of the trial.
It is natural to wonder whether our proposal to eliminate false negatives in drug approval
can also help eliminate false positives. That is, should our proposals be used to identify drugs
84

All phase III testing – usually two trials – is estimated to cost $205 million per drug than enters phase III. See
DiMasi, supra note 32, at 162.
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that have a no effect or a side effect for a patient subgroup, even though they are effective and
safe for the average patient and thus FDA-approvable? The answer is complicated. As we have
mentioned, adaptive trials are not helpful for identifying side effects.85 With respect to our other
proposals, the answer depends on whether there is reason to believe that the FDA has a skewed
incentive to disapprove helpful drugs.
The central problem that motivates our proposals is moral hazard by drug sponsors.
Sponsors have a financial incentive to find subgroups that show benefits from a drug whether or
not the subgroups actually benefit from the drug.86 Likewise our proposal are only useful as
against the FDA if it too suffers from moral hazard – though different in kind. If the FDA has an
incentive to disapprove a drug for certain patients even short of statistically significant evidence
that it harms them, perhaps because the agency is concerned about press criticism,87 then there is
also a reason to fear the FDA will overuse post hoc subgroup analysis to identify subgroups that
do not benefit from a drug.
If the FDA does not suffer such moral hazard, however, it should be allowed to conduct
the post hoc analysis to eliminate false positives. Since the FDA is conducting the analysis, it
knows the number of subgroups it has tested and thus can apply a multiple-testing penalty to its
own analysis. The only reform that we can unambiguously recommend to address false
negatives is that the FDA be sure to apply multiple testing penalties when it conducts or requires
that drug sponsors check side effects in certain subgroups.88 Just as data dredging allows a drug
company nearly always to find some subgroup of patients who appear to benefit from a drug, the
more subgroups the FDA tests for side effects, the more likely the agency will find side effects
when they do not actually exist.
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Adaptive trials use data from early enrollees to identify subgroups and then modify the trial to enroll more patients
from those subgroups so as to explore drug effects in those subgroups. When identifying subgroups with side
effects, this will require enrolling more people who one suspects will experience side effects. This is unethical and
unlikely to be approved by an Institutional Review Board. See the last paragraph of Section 3.b.ii.
86

Obviously sponsors should not be assigned the task of conducting post hoc subgroup analysis to identify
subgroups that do not benefit from a drug. While there is no risk of false negatives, the exercise would be
uninformative because the drug company has no incentive to report any subgroups not helped by the drug.
87

See Johnson and Winslow, supra note 58, at 1.
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A subtle point related to this reform is that the FDA ought not blindly to apply multiple testing penalties to
subgroups that a drug sponsor voluntarily offers up as experiencing side effects. The reason is that the sponsor has
an incentive to report that it tested far more subgroups than it actually did so as to raise the multiple testing penalty
for the subgroup that it does identify as having a side effect. In a backhanded way, this allow the drug sponsor to
look responsible – it offered up a subgroup that should not get its drug – but not actually lose any sales – the
multiple testing penalty would render the result for that subgroup insignificant. A better solution is for the FDA by
itself to conduct post hoc subgroup analysis designed to identify subgroups who do not benefit from a drug.
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Finally, we are aware that our paper raises a number of statistical questions, the answers
to which would help the FDA refine regulations that allow certain post hoc subgroup analyses to
inform approval decisions. For example: What is the proper multiple testing penalty for
adaptive design trials? Can sponsors use moments other than the variance, such as the mean or
skew, to identify subgroups in the no-outcome data analyses? What are the appropriate
proportions (20-80 or something different) to use when dividing a sample into an exploratory and
a confirmatory subsample? Should the multiple-testing penalty applied to tests on the
confirmatory subsample account for the fact that that subsample is smaller than the full sample?
Under what conditions will the no-outcome data analysis eliminate more false negatives than the
split-sample analysis. We leave these questions for future research by statisticians.
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Appendix
The table below summarizes the four basic options in a subgroup-identifying adaptive
design and our speculation as to the appropriate multiple-testing penalty. The rows indicate
whether interim analysis employed outcome data or not. The columns indicate whether the
sponsor added hypothesis tests after the interim analysis.
Table 1. Multiple testing penalties in adaptive trials.
Data used to identify
subgroups
Covariates (not outcomes)
Outcomes

Number of additional hypothesis tests added to study
Zero
One or more
No penalty
Penalty for adding one or more hypothesis
Must keep other subgroups in
Penalty for adding second hypothesis, must
evaluated population, plus a
keep other subgroups in evaluated population,
penalty for using outcome data
plus pay a penalty for using outcome data

If outcome data are not used to identify subgroups and no additional hypothesis tests are
added to the study, then there is no need to impose a multiple testing penalty, so long as the trial
must proceed until the sample size specified prior to starting the trial is achieved. The reason is
there was no testing of treatment effects in the interim analysis and the number of tests remain
the same as when the trial began. Even though the sponsor may choose a subgroup with low
variance with respect to covariate characteristics, so long as the data employed in the interim
analysis (patients’ baseline characteristics) are unrelated to the data relevant for estimation of the
treatment effect (patients’ treatment assignment and health outcomes), there is in essence
additional testing of treatment effects in the interim analysis. The general idea is, so long as one
analyzes a subset of the final data set that contains no information about treatment effects and
does not increase the number hypotheses to be tested, there is no multiple testing penalty for
changing the nature of the hypothesis to be tested with the final data.
If outcome data were used to identify subgroups, there should be a multiple testing
penalty even if no additional hypothesis tests were added. The reason is that the sponsor was
able to test whether treatment effects are significantly positive for a subgroup during the interim
analysis. Even with that subset of the final sample, it is highly likely that data mining would
uncover at least one subgroup with significant treatment effects in the subsample. As a result,
the sponsor would have been given the option to change the hypothesis test’s scope based on
treatment effects. It must pay a price for that.
This price is difficult to calculate since we may not know how many tests were
performed to identify a subgroup. It helps if that the IDMC conducts the interim analysis
because it has less incentive to engage in data mining and in any case is more likely truthfully to
report the number of tests performed. But if the sponsor has a role on that committee or the
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IDMC is not otherwise truly independent, institutional design may not help with calculating the
multiple-testing adjustment.89
In the cases where the sponsor adds one or more hypothesis to the study, it must pay an
additional price for multiple testing on top of the price it pays based on the data employed to
conduct the interim analysis. The reason for this penalty is obvious – the number of hypothesis
test has increased – and the size of the incremental penalty is straightforward to calculate.
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In that case, we speculate – though have not confirmed – that requiring the sponsor to include the excluded groups
along with the newly targeted subgroup in the final analysis may address the problem that the FDA may not know
the number of tests performed in the interim analysis. Suppose, for example, that interim analysis after 10% of the
sample is enrolled reveals that only young patients have a significant treatment effect. We recommend, when the
sponsor tests the hypothesis that the treatment effect among young patients in its final empirical analysis, that the
sponsor be required to use the entire sample and not just young subjects. Specifically, the sample tested should
include the elderly patients from the initial 10% sample even though they are not nominally the subject of the
hypothesis test. Our crude logic is that the larger the number of tests performed, the worse the relative performance
of subgroups excluded from the modified hypothesis test, and the larger is the cost or penalty to the sponsor of
having to include the excluded subgroups in the final empirical analysis. Including the elderly from the 10% sample
automatically make it less likely that the sponsor will be able to show that the drug works among young patients.
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Tables and figures

Table 2. Subgroup treatment effects in trial 0211 and trial 9801.
Trial 0211
Group

Trial 9801

n

RH

raw p-value

n

RH

raw p-value

554

0.78

0.1

251

0.61

0.05

Yes

140

1.71

0.059

93

0.94

0.86

No

414

0.56

0.002

158

0.48

0.03

Yes

259

0.59

0.032

109

0.47

0.046

No

295

0.92

0.69

142

0.74

0.37

Tx ≤ 2 wks

274

0.6

0.022

119

0.78

0.5

2 < Tx ≤ 4 wks

161

0.78

0.41

69

0.63

0.29

Tx > 4 wks

119

1.23

0.5

63

0.33

0.09

No

315

0.67

0.06

155

0.57

0.07

Yes

239

0.91

0.66

96

0.72

0.42

Low

258

0.53

0.012

121

0.76

0.44

High

254

1.02

0.92

96

0.7

0.41

USA

185

0.39

0.0048

123

0.76

0.45

Netherlands

11

5.6

0.14

54

0.38

0.074

Canada

163

0.72

0.26

46

0.4

0.14

21

1.11

0.89

7

0.82

0.89

All
PT controlled?

Newly diagnosed?

Time from BM to Tx

Prior chemotherapy

Trail B score

Country

UK
France

0
117

1.49

0.21

Germany
47
0.61
0.26
0
Notes. RH = relative hazard for MGd plus whole brain radiation therapy (WBRT) versus
WBRT. Raw p-value does not adjust for multiple testing. Trial 9801 was original Phase III
trial. Trial 0211 was second Phase III trial. PT = primary tumor. BM = brain metastases. Tx
= treatment in treatment or control group.
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Table 3. Identification of subgroups in non-outcome analysis: ratio of variance for baseline characteristics in 0211
trial versus 9801 trial.
Covariate
Ratio
p-value
Extracranial metastases?
1.73
0.0006
USA?
0.89
0.0006
PT controlled?
0.81
0.0025
Canada?
1.39
0.0068
PT resected without recurrence?
0.50
0.0137
Baseline Trail B score
1.63
0.0158
PT is large cell carcinoma?
0.60
0.0267
Days from diagnosis to randomization
5.29
0.0267
PT treated, <=1 month follow-up?
1.72
0.0554
PT is non-small-cell carcinoma?
0.80
0.1200
RPA status
0.71
0.1519
Baseline weight
1.27
0.2171
Sex
0.98
0.2171
PT has squamous histology?
0.78
0.2249
PT treated, >1 month follow-up?
0.85
0.2249
PT treated and progressing?
1.24
0.2734
PT has other histology?
1.90
0.3143
Prior chemotherapy?
1.04
0.4045
Baseline delay score
0.90
0.4045
Baseline COWA score
0.88
0.4045
Baseline Trail A score
0.59
0.4045
Baseline height
1.11
0.4075
Multiple BM lesions?
0.89
0.4154
PT newly diagnosed and/or untreated?
1.01
0.5843
Age 65+?
0.96
0.6924
Karnofsky Performance Score >= 90?
1.01
0.7010
PT is adenocarcinoma?
0.99
0.8469
Caucasian?
1.07
0.8469
Baseline recall score
0.97
0.8469
Baseline recognition score
0.98
0.9619
Other race?
1.00
0.9931
Notes. P-value adjusts for multiple testing. PT = primary tumor (i.e.,
lung cancer). BM = brain metastasis.
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Table 4. Treatment effect in 0211 trial for subgroups identified by no-outcome data analysis.
Relative hazard
p-value
Canada? No
0.82
0.3782
Canada? Yes
0.72
0.3782
Extracranial metastases? - Low
0.85
0.5467
Extracranial metastases? - High
0.71
0.2800
PT is large cell carcinoma? No
0.78
0.2800
PT is large cell carcinoma? Yes
0.90
0.8853
Days from diagnosis to randomization - Low
0.55
0.0325
Days from diagnosis to randomization - High
1.14
0.6646
USA? No
0.99
0.9500
USA? Yes
0.39
0.0325
Baseline Trail B score - Low
0.50
0.0480
Baseline Trail B score - High
0.96
0.8853
PT controlled? No
0.56
0.0320
PT controlled? Yes
1.71
0.1573
PT resected without recurrence? No
0.73
0.1536
PT resected without recurrence? Yes
3.07
0.3378
Notes. Relative hazard is for subjects on MGD and WBRT versus subjects on
WBRT only. P-value adjusts for multiple testing.
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Table 5. Identification of subgroups in split sample analysis: treatment effects in exploratory sample of 0211 trial.
Raw
Value A
Value B
Factor
p-value
Value
n
RH
p-value
Value
n
RH
p-value
france
9.11
0.027
0.0
84
0.32
0.05363
1.0
24 2.94
0.17954
pr.carbo
10.87
0.048
0.0
83
0.39
0.07833
1.0
25 4.26
0.18103
ptstagen
0.21
0.059
3.0
-1.72
0.42139
5.0
-0.37
0.07388
neurbl20
12.67
0.088
0.0
98
0.63
0.28314
1.0
10 7.99
0.14457
ltmptbm
0.20
0.098
0.0
49
1.32
0.61953
1.0
59 0.27
0.09389
sympbl12
4.67
0.100
0.0
-0.47
0.12400
2.0
-2.18
0.36172
neurbl18
0.22
0.110
5.0
-0.63
0.29587
5.0
-0.63
0.29587
basetrla
2.08
0.130
-0.3
-0.51
0.15601
2.7
-1.06
0.90295
euroaus
3.86
0.130
0.0
64
0.34
0.11599
1.0
44 1.33
0.61980
metachro
4.25
0.130
0.0
58
0.28
0.11374
1.0
50 1.19
0.73841
prior
3.66
0.140
0.0
67
0.40
0.13240
1.0
41 1.48
0.53320
neurbl21
2.44
0.150
0.0
-0.57
0.24937
1.0
-1.40
0.54303
sympbl7
4.71
0.150
0.0
-0.57
0.19931
0.0
-0.57
0.19931
prantflg
5.46
0.160
0.0
86
0.54
0.20250
1.0
22 2.97
0.33156
bmlesn
5.17
0.170
0.0
25
0.20
0.14510
1.0
83 1.01
0.98116
sympbl2
1.96
0.170
0.0
-0.47
0.16551
1.0
-0.92
0.84827
f.prrad
0.26
0.180
0.0
84
1.02
0.95880
1.0
24 0.27
0.13672
pr.csca
3.23
0.180
0.0
68
0.42
0.15428
1.0
40 1.37
0.61691
karnofsk
1.80
0.190
80.0
-0.51
0.16114
90.0
-0.92
0.85675
ltmptdx
0.28
0.190
0.0
51
1.09
0.86437
1.0
57 0.31
0.14175
neversmk
4.81
0.210
0.0
101 0.58
0.23766
1.0
7
2.80
0.37554
prantday
1.46
0.210
0.0
-0.55
0.21645
44.5
-0.80
0.62516
pbm.all
4.57
0.220
0.0
100 0.59
0.24367
1.0
8
2.68
0.39687
txgt1.4
3.57
0.220
0.0
90
0.58
0.23659
1.0
18 2.06
0.43119
controll
3.46
0.230
0.0
86
0.57
0.22919
1.0
22 1.98
0.45638
motorlbl
0.38
0.240
5.0
-0.71
0.45018
5.0
-0.71
0.45018
Notes. Value A is 0 for binary variables and the first quartile for continuous variables. Value B is 1 for binary
variables and the third quartile for continuous variables. Values are specified in the columns labeled value.
Sample size is given in columns labeled “n”. RH = relative hazard for MGd plus whole brain radiation therapy
(WBRT) versus WBRT. P-value for Value A and Value B adjusts for multiple testing. Factor gives the ratio of
variance at Value A and Value B. P-value for factor does not adjust for multiple testing.

Table 6. Distribution of p-values for "uncontrolled" subgroup treatment effects, by sample, in various sample splits.
P-value ranges
00.010.050.100.250.01
0.05
0.10
0.25
1
Total
Exploratory sample
16
19
11
19
35
100
Validation sample (raw p-values)
14
18
2
1
0
35
Validation sample (adj p-values)
2
9
9
10
4
35
Notes. First row gives distribution of p-values for “uncontrolled” subgroup across 100 sample splits after
adjusting for multiple testing. Second and third rows gives distribution of p-values in the validation sample for the
35 splits where uncontrolled group is selected in exploratory sample, i.e., adjusted p-value for uncontrolled
subgroup in exploratory sample is less than 0.05. P-values in second row do not adjust for multiple testing. Pvalues in the third row apply an overly conservative Bonferroni adjustment for multiple testing.
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